In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.

The Swedish firm has treated the first two patients in a Phase I/II trial of the autologous neoantigen-directed lymphocyte therapy.

The company also continues to study Descartes-08 in other autoimmune diseases and has plans for a basket trial in pediatric patients.

The FDA didn't approve the therapy in EBV-positive post-transplant lymphoproliferative disease due to findings at a third-party manufacturing facility.

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.

Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...